Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies

The main study will comprise several sub-studies evaluating PM54 in combination with different anticancer agents, starting with the following combinations: PM54 plus irinotecan and PM54 plus doxorubicin. Each sub-study includes Part 1 (Dose Escalation) and Part 2 (Dose Expansion). In Part 1, participants with advanced malignancies of selected tumor types will receive escalated doses of PM54 in combination with the relevant anticancer agent until a suitable dose is established, or until clinical or objective disease progression, withdrawal of consent, or unacceptable or cumulative toxicity occurs. In Part 2, participants with advanced malignancies will receive the recommended dose combination of PM54 and the relevant combination product identified during Part 1 of the corresponding sub-study.